ClinicalTrials.gg
CompletedNCT01243944Updated Mar 6, 2019Results posted

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

A Phase 3 interventional study of ruxolitinib tablets and Best Available Therapy (BAT) in Polycythemia Vera, sponsored by Incyte Corporation. Completed at 102 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.

Enrollment
3rd of 17
222 · median 110
Started
2010
with 1 other
Phase 3
5 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
3 of 17
Incyte Corporation

Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 3rd registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing ruxolitinib in Polycythemia Vera, or all of them as a file.
02

Study summary

This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • INCB018424
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria
  • Participants resistant to or intolerant of hydroxyurea
  • Participants with a phlebotomy requirement
  • Participants with splenomegaly (palpable or non-palpable) and a spleen volume, as measured by MRI (or CT in applicable participants ), of greater than or equal to 450 cubic centimeters
  • Participants with an (ECOG) performance status of 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing
  • Participants with inadequate liver or renal function
  • Participants with significant bacterial, fungal, parasitic, or viral infection requiring treatment
  • Participants with an active within the past 5 years, excluding specific skin cancers
  • Participants with known active hepatitis or positivity
  • Participants who have previously received treatment with a JAK inhibitor
  • Participants being treated with any agent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    ruxolitinib tablets

    Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy

    Drug: ruxolitinib tablets

  • Other
    Best Available Therapy

    Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

    Other: Best Available Therapy (BAT)

Interventions

  • DrugRuxolitinibStudies of RuxolitinibRuxolitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy

  • OtherBest Available Therapy (BAT)

    Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

    Also known as: BAT could include:, Hydroxyurea, IFN/PEG-IFN, Pipobroman, Anagrelide, Lenalidomide, Pomalidomide, Observation only

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Achieving a Primary Response at Week 32

    Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32).

    Time frame: 32 Weeks

Secondary outcomes

  1. The Percentage of Participants Achieving a Durable Primary Response at Week 48

    Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.

    Time frame: 48 Weeks

  2. The Percentage of Participants Achieving Complete Hematological Remission at Week 32

    Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\^9/L and a white blood cell count less than or equal to 10 X 10\^9/L.

    Time frame: 32 Weeks

  3. The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48

    Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization.

    Time frame: 48 Weeks

  4. The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48

    Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization.

    Time frame: 48 Weeks

  5. The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48

    Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.

    Time frame: 48 Weeks

  6. Estimated Duration of the Primary Response

    Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response). Kaplan-Meier estimates are provided for duration of primary response.

    Time frame: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study

  7. The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32

    Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.

    Time frame: 32 Weeks

  8. The Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48

    Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization.

    Time frame: 48 Weeks

  9. Estimated Duration of the Complete Hematological Remission

    Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response). Kaplan-Meier estimates are provided for duration of complete hematological remission.

    Time frame: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study

  10. Duration of the Absence of Phlebotomy Eligibility

    Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.

    Time frame: 256 Weeks

  11. Duration of Reduction in Spleen Volume

    Duration of spleen volume reduction is defined as the time from the first occurrence of a \>=35% reduction from baseline in spleen volume until the date of the first documented progression.

    Time frame: 256 Weeks

  12. Duration of The Overall Clinicohematologic Response

    Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.

    Time frame: 256 Weeks

07

Results

Posted Mar 6, 2015

Participant flow

Participants may be treated beyond 256 weeks due to the 14 day visit window.

Participant flow — Overall Study
MilestoneRuxolitinibBest Available Therapy
Started110112
Treated110111
Followed for survival2221
Completed6561
Not completed4551
Withdrew: Adverse event1513
Withdrew: Lost to follow-up21
Withdrew: Physician decision27
Withdrew: Disease progression1211
Withdrew: Protocol deviation11
Withdrew: Participant decision1015
Withdrew: Death23
Withdrew: Non-compliance with study treatment10

Outcome measures

PrimaryThe Percentage of Participants Achieving a Primary Response at Week 32

Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32).

Time frame:
32 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving a Primary Response at Week 32
percentage of participantsRuxolitinibBest Available Therapy
The Percentage of Participants Achieving a Primary Response at Week 3222.7 (15.3 to 31.7)0.9 (0.0 to 4.9)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Exact Cochran-Mantel-Haenszel · p = < 0.0001 · Odds ratio, log: 32.67 · 95% CI 5.04 to 1337
SecondaryThe Percentage of Participants Achieving a Durable Primary Response at Week 48

Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving a Durable Primary Response at Week 48
percentage of participantsRuxolitinibBest Available Therapy
The Percentage of Participants Achieving a Durable Primary Response at Week 4820.0 (13.0 to 28.7)0.9 (0.0 to 4.9)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Exact Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 28.01 · 95% CI 4.24 to 1144
SecondaryThe Percentage of Participants Achieving Complete Hematological Remission at Week 32

Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\^9/L and a white blood cell count less than or equal to 10 X 10\^9/L.

Time frame:
32 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving Complete Hematological Remission at Week 32
percentage of participantsRuxolitinibBest Available Therapy
The Percentage of Participants Achieving Complete Hematological Remission at Week 3223.6 (16.1 to 32.7)8.0 (3.7 to 14.7)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Exact Cochran-Mantel-Haenszel · p = 0.0016 · Odds ratio (or): 3.57 · 95% CI 1.50 to 9.06P-value was calculated using stratified exact Cochran-Mantel-Haenszel test by adjusting for the WBC/platelet status (abnormal vs normal) at baseline.
SecondaryThe Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48

Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization.

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48
percentage of participantsRuxolitinibBest Available Therapy
The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 4820.9 (13.7 to 29.7)0.9 (0.0 to 4.9)
SecondaryThe Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48

Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization.

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48
percentage of participantsRuxolitinibBest Available Therapy
The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 4854.5 (44.8 to 64.1)1.8 (0.2 to 6.3)
SecondaryThe Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48

Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48
percentage of participantsRuxolitinibBest Available Therapy
The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 4837.3 (28.2 to 47.0)0.9 (0.0 to 4.9)
SecondaryEstimated Duration of the Primary Response

Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response). Kaplan-Meier estimates are provided for duration of primary response.

Time frame:
Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
Reported as:
Number · probability
Estimated Duration of the Primary Response
probabilityRuxolitinib
16 weeks1.00 (NA to NA)
32 weeks1.00 (NA to NA)
48 weeks0.92 (0.72 to 0.98)
64 weeks0.92 (0.72 to 0.98)
80 weeks0.92 (0.72 to 0.98)
96 weeks0.88 (0.67 to 0.96)
112 weeks0.84 (0.62 to 0.94)
128 weeks0.84 (0.62 to 0.94)
144 weeks0.84 (0.62 to 0.94)
160 weeks0.79 (0.57 to 0.91)
176 weeks0.79 (0.57 to 0.91)
192 weeks0.74 (0.51 to 0.88)
208 weeks0.74 (0.51 to 0.88)
224 weeks0.74 (0.51 to 0.88)
240 weeksNA (NA to NA)
256 weeksNA (NA to NA)
SecondaryThe Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32

Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.

Time frame:
32 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32
percentage of participantsRuxolitinibBest Available Therapy
Complete response rate8.20.9
Partial response rate54.518.8
SecondaryThe Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48

Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization.

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48
percentage of participantsRuxolitinibBest Available Therapy
Complete response rate7.30.9
Partial response rate50.90.9
SecondaryEstimated Duration of the Complete Hematological Remission

Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response). Kaplan-Meier estimates are provided for duration of complete hematological remission.

Time frame:
Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
Reported as:
Number · probability
Estimated Duration of the Complete Hematological Remission
probabilityRuxolitinib
16 weeks1.00 (NA to NA)
32 weeks1.00 (NA to NA)
48 weeks0.88 (0.66 to 0.96)
64 weeks0.83 (0.61 to 0.93)
80 weeks0.74 (0.51 to 0.87)
96 weeks0.74 (0.51 to 0.87)
112 weeks0.69 (0.46 to 0.84)
128 weeks0.69 (0.46 to 0.84)
144 weeks0.65 (0.41 to 0.81)
160 weeks0.65 (0.41 to 0.81)
176 weeks0.55 (0.32 to 0.73)
192 weeks0.55 (0.32 to 0.73)
208 weeks0.55 (0.32 to 0.73)
224 weeks0.55 (0.32 to 0.73)
240 weeksNA (NA to NA)
256 weeksNA (NA to NA)
SecondaryDuration of the Absence of Phlebotomy Eligibility

Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.

Time frame:
256 Weeks
Reported as:
Number · probability
Duration of the Absence of Phlebotomy Eligibility
probabilityRuxolitinib
16 weeks1.00 (NA to NA)
32 weeks1.00 (NA to NA)
48 weeks0.97 (0.88 to 0.99)
64 weeks0.92 (0.82 to 0.97)
80 weeks0.91 (0.80 to 0.96)
96 weeks0.91 (0.80 to 0.96)
112 weeks0.87 (0.76 to 0.93)
128 weeks0.84 (0.72 to 0.91)
144 weeks0.84 (0.72 to 0.91)
160 weeks0.82 (0.70 to 0.90)
176 weeks0.79 (0.66 to 0.87)
192 weeks0.77 (0.64 to 0.86)
208 weeks0.73 (0.60 to 0.83)
224 weeks0.73 (0.60 to 0.83)
240 weeks0.73 (0.60 to 0.83)
256 weeks0.73 (0.60 to 0.83)
SecondaryDuration of Reduction in Spleen Volume

Duration of spleen volume reduction is defined as the time from the first occurrence of a \>=35% reduction from baseline in spleen volume until the date of the first documented progression.

Time frame:
256 Weeks
Reported as:
Number · probability
Duration of Reduction in Spleen Volume
probabilityRuxolitinib
16 weeks1.00 (NA to NA)
32 weeks1.00 (NA to NA)
48 weeks1.00 (NA to NA)
64 weeks1.00 (NA to NA)
80 weeks1.00 (NA to NA)
96 weeks0.98 (0.84 to 1.00)
112 weeks0.95 (0.82 to 0.99)
128 weeks0.95 (0.82 to 0.99)
144 weeks0.95 (0.82 to 0.99)
160 weeks0.93 (0.79 to 0.98)
176 weeks0.93 (0.79 to 0.98)
192 weeks0.93 (0.79 to 0.98)
208 weeks0.87 (0.66 to 0.95)
224 weeks0.72 (0.34 to 0.91)
240 weeksNA (NA to NA)
256 weeksNA (NA to NA)
SecondaryDuration of The Overall Clinicohematologic Response

Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.

Time frame:
256 Weeks
Reported as:
Number · probability
Duration of The Overall Clinicohematologic Response
probabilityRuxolitinib
16 weeks1.00 (NA to NA)
32 weeks0.99 (0.90 to 1.00)
48 weeks0.96 (0.87 to 0.99)
64 weeks0.91 (0.81 to 0.96)
80 weeks0.88 (0.78 to 0.94)
96 weeks0.88 (0.78 to 0.94)
112 weeks0.85 (0.74 to 0.92)
128 weeks0.82 (0.71 to 0.89)
144 weeks0.82 (0.71 to 0.89)
160 weeks0.80 (0.69 to 0.88)
176 weeks0.75 (0.63 to 0.84)
192 weeks0.70 (0.57 to 0.80)
208 weeks0.67 (0.54 to 0.77)
224 weeks0.67 (0.54 to 0.77)
240 weeks0.67 (0.54 to 0.77)
256 weeks0.67 (0.54 to 0.77)

Adverse events

Collected over The initial data reported was for the study up to Week 32. This time frame defines the comparative phase of the study where the majority of participants remained on their original randomized assignment and exposure between ruxolitinib and best available therapy was similar. Data inclusive of end of study was reported up to week 256 for Ruxolitinib group. Long term Follow Up for BAT was not reported as all patients have completed the study or crossed over to Ruxolitinib group by week 80.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib - Through Week 32—15/110 (13.6%)105/110 (95.5%)
Best Available Therapy - Through Week 32—10/111 (9%)104/111 (93.7%)
Ruxolitinib - Week 256 Close Out—44/110 (40%)107/110 (97.3%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventRuxolitinib - Through Week 32Best Available Therapy - Through Week 32Ruxolitinib - Week 256 Close Out
PneumoniaInfections and infestations1/1101/1115/110
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1100/1114/110
Atrial fibrillationCardiac disorders0/1101/1113/110
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1100/1113/110
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1100/1113/110
Chest painGeneral disorders1/1100/1112/110
DehydrationMetabolism and nutrition disorders0/1100/1112/110
Metastatic squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1100/1112/110
Rectal haemorrhageGastrointestinal disorders0/1100/1112/110
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1100/1112/110
Most frequent other events
Showing 10 of 56
Most frequent other events
EventRuxolitinib - Through Week 32Best Available Therapy - Through Week 32Ruxolitinib - Week 256 Close Out
AnaemiaBlood and lymphatic system disorders20/1103/11138/110
DiarrhoeaGastrointestinal disorders16/1108/11130/110
PruritusSkin and subcutaneous tissue disorders15/11025/11130/110
Weight increasedInvestigations6/1101/11126/110
HeadacheNervous system disorders18/11021/11125/110
ArthralgiaMusculoskeletal and connective tissue disorders8/1107/11124/110
FatigueGeneral disorders16/11017/11122/110
Muscle spasmsMusculoskeletal and connective tissue disorders13/1105/11122/110
CoughRespiratory, thoracic and mediastinal disorders9/1106/11120/110
DyspnoeaRespiratory, thoracic and mediastinal disorders11/1102/11119/110

Baseline characteristics

All enrolled participants, regardless treated or not.

Age, Continuous
Age, Continuous(years)RuxolitinibBest Available TherapyTotal
Mean61.1 ± 10.4859.1 ± 10.2560.1 ± 10.39
Age, Customized
Age, Customized(participants)RuxolitinibBest Available TherapyTotal
< 60 years4954103
≥ 60 years6158119
Sex: Female, Male
Sex: Female, Male(Participants)RuxolitinibBest Available TherapyTotal
Female443276
Male6680146
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RuxolitinibBest Available TherapyTotal
White/Caucasian9896194
Black/African American101
Asian111627
Weight
Weight(kg)RuxolitinibBest Available TherapyTotal
Mean76.6 ± 14.0979.0 ± 17.3477.8 ± 15.83
Height
Height(cm)RuxolitinibBest Available TherapyTotal
Mean172.2 ± 8.44173.3 ± 9.79172.8 ± 9.14
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)RuxolitinibBest Available TherapyTotal
Mean25.8 ± 3.8226.1 ± 4.2425.9 ± 4.03
ECOG performance status
ECOG performance status(participants)RuxolitinibBest Available TherapyTotal
07677153
1313465
2314
08

Study locations

102 sites
  • Birmingham, Alabama, United States
  • Scottsdale, Arizona, United States
  • Pomona, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Bridgeport, Connecticut, United States
  • New Haven, Connecticut, United States
  • Boynton Beach, Florida, United States
  • Fort Myers, Florida, United States
  • Jacksonville, Florida, United States
  • Winter Park, Florida, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Lafayette, Louisiana, United States
  • Scarborough, Maine, United States
  • Baltimore, Maryland, United States
  • Columbia, Maryland, United States
  • Southfield, Michigan, United States
  • Jefferson City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Morristown, New Jersey, United States
  • Somerville, New Jersey, United States
  • Charleston, South Carolina, United States
  • Greenville, South Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Buenos Aires, Argentina
  • Brisbane, Australia
  • Parkville, Australia
  • Tweed Heads, Australia
  • Antwerp, Belgium
  • Brugge, Belgium
  • Bruxelles, Belgium
  • Leuven, Belgium
  • Hamilton, Canada
  • Montreal, Canada
  • Toronto, Canada
  • Beijing, China
  • Hangzhou, China
  • Avignon, France
  • Bayonne, France
  • Brest, France
  • Lille, France
  • Nantes, France
  • Paris, France
  • Vandœuvre-lès-Nancy, France
  • Aachen, Germany
  • Berlin, Germany
  • Bonn, Germany
  • Freiburg, Germany
  • Hamburg, Germany
  • Jena, Germany
  • Magdeburg, Germany
  • Mannheim, Germany
  • Minden, Germany
  • Munchen, Germany
  • Ulm, Germany
  • Budapest, Hungary
  • Kecskemet, Hungary
  • Szeged, Hungary
  • Szombathely, Hungary
  • Bari, Italy
  • Bergamo, Italy
  • Bologna, Italy
  • Firenze, Italy
  • Milano, Italy
  • Napoli, Italy
  • Orbassano, Italy
  • Pavia, Italy
  • Reggio Calabria, Italy
  • Roma, Italy
  • Varese, Italy
  • Vicenza, Italy
  • Chiba, Japan
  • Chuo-city Yamanashi, Japan
  • Maebashi, Japan
  • Nagoya-city Aichi, Japan
  • Osaka, Japan
  • Tokyo, Japan
  • Seoul, Korea, Republic of
  • Enschede, Netherlands
  • Rotterdam, Netherlands
  • Moscow, Russian Federation
  • St. Petersburg, Russian Federation
  • Barcelona, Spain
  • Coruña, Spain
  • Las Palmas de Gran Canaria, Spain
  • Madrid, Spain
  • Majadahonda, Spain
  • Malaga, Spain
  • Pamplona, Spain
  • Salamanca, Spain
  • Valencia, Spain
  • Bangkok, Thailand
  • Ankara, Turkey
  • Istanbul, Turkey
  • Izmir, Turkey
  • Bournemouth, United Kingdom

Showing the first 100 of 102 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. PubMed 31982039 ↗
  • Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2. PubMed 29396713 ↗
  • Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017 May;56:52-59. doi: 10.1016/j.leukres.2017.01.032. Epub 2017 Jan 31. PubMed 28193568 ↗
  • Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21. PubMed 27102499 ↗
  • Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002. PubMed 25629741 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in Jan 2014, 38 months.

Results were first posted in Mar 2015, 1 year 1 month after primary completion. A results delay was requested in Dec 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2010
First posted
Nov 19, 2010
StartActual
Oct 27, 2010
Primary completionActual
Jan 15, 2014
CompletionActual
Feb 9, 2018
Results delay requested
Dec 13, 2010
Results first posted
Mar 6, 2015
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01243944
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 19, 2010
Start date
Oct 27, 2010
Primary completion
Jan 15, 2014
Completion
Feb 9, 2018
Results posted
Mar 6, 2015
Last update
Mar 6, 2019

Study contacts

Srdan Verstovsek, MD,PhD
study director · M.D. Anderson Cancer Center
Mark Jones, MD
study director · Incyte Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion